Logo image of XFOR

X4 PHARMACEUTICALS INC (XFOR) Stock Fundamental Analysis

NASDAQ:XFOR - Nasdaq - US98420X1037 - Common Stock - Currency: USD

1.49  -0.04 (-2.61%)

After market: 1.54 +0.05 (+3.36%)

Fundamental Rating

2

Taking everything into account, XFOR scores 2 out of 10 in our fundamental rating. XFOR was compared to 556 industry peers in the Biotechnology industry. XFOR has a bad profitability rating. Also its financial health evaluation is rather negative. XFOR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

XFOR had negative earnings in the past year.
XFOR had a negative operating cash flow in the past year.
In the past 5 years XFOR always reported negative net income.
XFOR had a negative operating cash flow in each of the past 5 years.
XFOR Yearly Net Income VS EBIT VS OCF VS FCFXFOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

XFOR has a better Return On Assets (11.23%) than 94.78% of its industry peers.
Looking at the Return On Equity, with a value of 63.62%, XFOR belongs to the top of the industry, outperforming 98.92% of the companies in the same industry.
Industry RankSector Rank
ROA 11.23%
ROE 63.62%
ROIC N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
XFOR Yearly ROA, ROE, ROICXFOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

XFOR's Profit Margin of 46.54% is amongst the best of the industry. XFOR outperforms 99.10% of its industry peers.
The Gross Margin of XFOR (82.42%) is better than 86.87% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 46.54%
GM 82.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XFOR Yearly Profit, Operating, Gross MarginsXFOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

XFOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XFOR has more shares outstanding
XFOR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for XFOR is higher compared to a year ago.
XFOR Yearly Shares OutstandingXFOR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
XFOR Yearly Total Debt VS Total AssetsXFOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -7.49, we must say that XFOR is in the distress zone and has some risk of bankruptcy.
XFOR has a worse Altman-Z score (-7.49) than 67.45% of its industry peers.
XFOR has a Debt/Equity ratio of 3.30. This is a high value indicating a heavy dependency on external financing.
XFOR has a Debt to Equity ratio of 3.30. This is amonst the worse of the industry: XFOR underperforms 82.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.3
Debt/FCF N/A
Altman-Z -7.49
ROIC/WACCN/A
WACC10.22%
XFOR Yearly LT Debt VS Equity VS FCFXFOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 3.70 indicates that XFOR has no problem at all paying its short term obligations.
XFOR has a Current ratio of 3.70. This is comparable to the rest of the industry: XFOR outperforms 42.99% of its industry peers.
A Quick Ratio of 3.58 indicates that XFOR has no problem at all paying its short term obligations.
XFOR has a Quick ratio (3.58) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 3.58
XFOR Yearly Current Assets VS Current LiabilitesXFOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.90% over the past year.
EPS 1Y (TTM)35.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

XFOR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.05% yearly.
The Revenue is expected to grow by 145.58% on average over the next years. This is a very strong growth
EPS Next Y54.3%
EPS Next 2Y23.17%
EPS Next 3Y23.18%
EPS Next 5Y14.05%
Revenue Next Year1503.22%
Revenue Next 2Y211.1%
Revenue Next 3Y271.06%
Revenue Next 5Y145.58%

3.3 Evolution

XFOR Yearly Revenue VS EstimatesXFOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
XFOR Yearly EPS VS EstimatesXFOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XFOR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XFOR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XFOR Price Earnings VS Forward Price EarningsXFOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XFOR Per share dataXFOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15 -20

4.3 Compensation for Growth

XFOR's earnings are expected to grow with 23.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.17%
EPS Next 3Y23.18%

More info and screens

0

5. Dividend

5.1 Amount

XFOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

X4 PHARMACEUTICALS INC

NASDAQ:XFOR (7/22/2025, 7:25:52 PM)

After market: 1.54 +0.05 (+3.36%)

1.49

-0.04 (-2.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners51.93%
Inst Owner Change-0.06%
Ins Owners2.45%
Ins Owner Change75.76%
Market Cap8.84M
Analysts83.64
Price Target36.92 (2377.85%)
Short Float %6.89%
Short Ratio1.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.42%
Min EPS beat(2)-12.04%
Max EPS beat(2)100.88%
EPS beat(4)1
Avg EPS beat(4)-303.78%
Min EPS beat(4)-1301.88%
Max EPS beat(4)100.88%
EPS beat(8)3
Avg EPS beat(8)-155.06%
EPS beat(12)6
Avg EPS beat(12)-100.65%
EPS beat(16)7
Avg EPS beat(16)-78.4%
Revenue beat(2)2
Avg Revenue beat(2)674.26%
Min Revenue beat(2)35.03%
Max Revenue beat(2)1313.49%
Revenue beat(4)3
Avg Revenue beat(4)344.75%
Min Revenue beat(4)-67.57%
Max Revenue beat(4)1313.49%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15.16%
PT rev (3m)1257.48%
EPS NQ rev (1m)4.11%
EPS NQ rev (3m)-2857.66%
EPS NY rev (1m)13.19%
EPS NY rev (3m)-1721.37%
Revenue NQ rev (1m)-9.02%
Revenue NQ rev (3m)-32.73%
Revenue NY rev (1m)16.04%
Revenue NY rev (3m)207.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.28
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-13.46
EYN/A
EPS(NY)-10.29
Fwd EYN/A
FCF(TTM)-20.23
FCFYN/A
OCF(TTM)-18.49
OCFYN/A
SpS5.29
BVpS3.87
TBVpS-0.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.23%
ROE 63.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 46.54%
GM 82.42%
FCFM N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 3.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 848.51%
Cap/Sales 32.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.7
Quick Ratio 3.58
Altman-Z -7.49
F-Score4
WACC10.22%
ROIC/WACCN/A
Cap/Depr(3y)318.09%
Cap/Depr(5y)293.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.51%
EPS Next Y54.3%
EPS Next 2Y23.17%
EPS Next 3Y23.18%
EPS Next 5Y14.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1503.22%
Revenue Next 2Y211.1%
Revenue Next 3Y271.06%
Revenue Next 5Y145.58%
EBIT growth 1Y1.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.53%
OCF growth 3YN/A
OCF growth 5YN/A